The DOI matches its Crossref record; 76 of the 80 references it cites were found in a registry or an index; 37 of the 111 sources its claims cite were checked for support.
Lactobacillus Bacteremia and Probiotics: A Review
Open accessAbstract
Lactobacilli are widely found in nature, are commensal microbes in humans, and are commonly used as probiotics. Concerns about probiotic safety have arisen due to reports of bacteremia and other Lactobacillus-associated infections. We reviewed the literature for articles on the pathogenicity of Lactobacillus spp. bacteremia and reports of probiotics in these patients. Our aim is to review these articles and update the present knowledge on the epidemiology of Lactobacillus spp. bacteremia and determine the role of probiotics in Lactobacillus bacteremia. Lactobacillus bacteremia is infrequent but has a higher risk of mortality and risk factors, including severe underlying diseases, immune system suppression, admission to intensive care units, and use of central venous catheters. A variety of Lactobacillus species may cause bacteremia and may or may not be associated with probiotic exposure. To determine if oral probiotics are the source of these infections, the blood isolates and the oral probiotic strain(s) must be compared by sensitive identification methods. The prevalence of Lactobacillus bacteremia is infrequent but is more common in patients taking probiotics compared to those not taking probiotics. Three probiotics (Lacticaseibacillus rhamnosus GG, Lactiplantibacillus plantarum, and Lacticaseibacillus paracasei) were directly linked with blood isolates from bacteremia patients using molecular identification assays.
Overview
CoChat Summary
TL;DR
This review finds Lactobacillus bacteremia (LB) is infrequent but associated with high mortality and risk factors including severe underlying disease, immunosuppression, ICU admission, and central venous catheters. Probiotic strains are an infrequent source: only 23 of 75 reviewed LB cases had a blood isolate identical to the probiotic strain taken, with Lacticaseibacillus rhamnosus GG most commonly implicated.
Key findings
- LB prevalence is low: 0.1–0.2% of blood culture isolates from hospitalized patients and 0.5% from immunocompromised patients; one hematopoietic cell transplant cohort reported 1.6 cases/100,000 patient days, and Finland averaged 0.29 cases/100,000 inhabitants/year from 1995–2000 despite increased Lcb. rhamnosus GG use.
- Mortality is high but often attributed to underlying conditions: estimated at 30%; Salminen et al. found 26% mortality at one month and 48% at one year; Husni et al. found 44% died during hospitalization but only one death was directly attributable to LB; Franko et al. reported 23.7% case fatality by day 28 and 45% at one year.
- Risk factors include severe underlying diseases (OR = 15.8 for mortality), while treatment with antibiotics effective in vitro was associated with lower mortality (OR = 0.22); in one review, 49% were in ICU, 40% had cancer, 37% immunosuppression, 29% central venous devices, and 39% had ≥2 risk factors.
- Among 75 total LB cases reviewed, 23 had a blood isolate identical to the probiotic strain taken; three probiotics were directly linked by molecular identification: Lcb. rhamnosus GG, Lactiplantibacillus plantarum, and Lcb. paracasei. In one pediatric ICU study, 6/522 (1.1%) patients receiving Lcb. rhamnosus GG developed LB versus 2/21,652 (0.009%) not receiving it; in pediatric hematopoietic cell transplant patients, 6/34 (17.6%) given a probiotic developed LB, with three matched to the probiotic blend.
Methods
- Literature review from 1980 to 2023 on Lactobacillus spp. bacteremia pathogenicity and probiotic reports in these patients.
- Search terms included Lactobacillus, bacteremia, probiotics, risk factors, treatment, antibiotic susceptibilities, safety, epidemiology, sepsis, endocarditis, and infection.
- Inclusion criteria were case reports, case series, observational studies, and reviews; exclusion criteria were non-Lactobacilli bacteremias, fungemias, or other diseases; references from reviews and published papers were also queried.
Limitations
- The paper states that many reports attempting to link probiotic strains to LB isolates failed to prove correlation because of incomplete identification of strains; molecular identification of both the blood isolate and the probiotic strain is needed.
- The paper states that clinical experience and clinical trials on optimal antibiotic treatments are lacking, and that more studies on length of hospital stay, healthcare-associated costs, and long-term surveillance of probiotic use and LB are warranted.
- Evident from the text: this is a literature review without a described systematic search or meta-analysis, and findings depend on heterogeneous case reports, case series, and observational studies with variable identification methods and incomplete strain reporting; LB may also be underdiagnosed because lactobacilli are difficult to culture and identify and are often deemed contaminants.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
24 Valid · 2 Not valid · 33 Not checked · 26 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“In general, second-generation cephalosporin and cefuroxime showed greater activity against lactobacilli, compared with third-generation cephalosporin and ceftriaxone, which is in accordance with earlier observations.”
§ Lactobacillus Bacteremia and Probiotics: A Review > 3. Results > 3.5. Treatment and Susceptibility
What the sources say
- Supportedcites [23] Salminen, 2006, Lactobacillus bacteremia, species identification, and antimicrobial susceptibility of 85 blood isolates, Clin. Infect. Dis. source
The Discussion directly states that cefuroxime, a second-generation cephalosporin, showed higher activity against lactobacilli than ceftriaxone, a third-generation cephalosporin. The β-Lactam antimicrobials section likewise reports generally highest activity for cefuroxime and lowest for ceftriaxone among the cephalosporins tested. (LLM, conf=0.95)
plainstates an associationn = 85- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The most common species isolated from LB blood samples is Lcb. rhamnosus GG (ATCC53103) [6,7,15,22,23,24].”
§ Lactobacillus Bacteremia and Probiotics: A Review > 3. Results > 3.2. Etiologies of LB
What the sources say
- Not checked — no full text of the sourcecites [6] Husni, 1997, Lactobacillus bacteremia and endocarditis: Review of 45 cases, Clin. Infect. Dis. source
- Partly supportedcites [7] Rossi, F., Amadoro, C., Gasperi, M., and Colavita, G. (2022). Lactobacilli Infection Case Reports in the Last Three Years and Safety Implications. Nutrients, 14. sourceExperimental — accuracy not yet measured
Section 4 (page unavailable) reports blood isolates identified as L. rhamnosus in patients receiving the GG probiotic, and Section 5 links blood isolates in one case to L. rhamnosus GG (ATCC 53103). Neither passage establishes that the GG strain was the most common isolate across lactobacilli blood samples; Section 4 also describes L. rhamnosus blood isolates more similar to other strains than to GG. (LLM, conf=0.86)
- Partly supportedcites [15] Doron, 2015, Risk and safety of probiotics, Clin. Infect. Dis. sourceExperimental — accuracy not yet measured
The surveillance passage (labelled Abstract in our copy; no page given) reports that 11 of 89 blood isolates appeared identical to L. rhamnosus GG by one test. It does not say GG was the most common isolate, and it notes that subsequent testing found phenotypic differences between those isolates and probiotic GG. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [22] Lu, 1999, Clones of Lactobacillus casei and Torulopsis glabrata associated with recurrent abdominal wall abscess, J. Formos. Med. Assoc.
- Partly supportedcites [23] Salminen, 2006, Lactobacillus bacteremia, species identification, and antimicrobial susceptibility of 85 blood isolates, Clin. Infect. Dis. sourceExperimental — accuracy not yet measured
The Results report that L. rhamnosus was the most numerous species (46 isolates), including 22 classified as L. rhamnosus GG type. The Identification section defines “GG type” by an indistinguishable PFGE pattern; the Isolates and patients section identifies ATCC 53103 as a separate reference strain used in testing. The paper therefore does not establish that the most common blood isolate was the exact ATCC 53103 strain. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [24] Gouriet, 2012, Lactobacillus rhamnosus bacteremia: An emerging clinical entity, Eur. J. Clin. Microbiol. Infect. Dis. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The source of these infections has sometimes been attributed to the use of Lactobacillus-containing probiotics [9,10,11].”
§ Lactobacillus Bacteremia and Probiotics: A Review > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [9] Salminen, 2004, Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG, Clin. Infect. Dis. source
- Supportedcites [10] Cohen, 2016, Incidence and outcomes of bloodstream infections among hematopoietic cell transplant recipients from species commonly reported to be in over-the-counter probiotic formulations, Transpl. Infect. Dis. source
The Discussion reports rare cases of Lactobacillus bacteremia after probiotic supplementation, supporting the claim that probiotics have sometimes been implicated. It also cautions that the authors could not determine whether probiotic use caused infections in their own cohort. (LLM, conf=0.90)
- Supportedcites [11] Dani, 2016, Lactobacillus Sepsis and Probiotic Therapy in Newborns: Two New Cases and Literature Review, AJP Rep. source
The Discussion reports two neonatal cases of L. rhamnosus GG sepsis during enteral supplementation and says probiotic supplementation most likely caused the sepsis in these patients and previously reported cases. It also describes enteral administration as the likely portal of entry, supporting the claim that these infections have sometimes been attributed to Lactobacillus-containing probiotics. (LLM, conf=0.94)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Other Lactobacillus species have been less frequently reported: Lcb. paracasei [7], Lactobacillus (L.) acidophilus [7,15], L. jensenii [7,23,26], Lactiplantibacillus (Lpb.) plantarum [7,27], and Limosilactobacillus (Lsb.) fermentum [7,23].”
§ Lactobacillus Bacteremia and Probiotics: A Review > 3. Results > 3.2. Etiologies of LB
What the sources say
- Supportedcites [7] Rossi, F., Amadoro, C., Gasperi, M., and Colavita, G. (2022). Lactobacilli Infection Case Reports in the Last Three Years and Safety Implications. Nutrients, 14. source
The Abstract (page not available in our copy) lists all five species among reported lactobacilli infections. Each has fewer reported cases than Lacticaseibacillus rhamnosus, supporting the statement that they were less frequently reported. (LLM, conf=0.92)
- Partly supportedcites [15] Doron, 2015, Risk and safety of probiotics, Clin. Infect. Dis. sourceExperimental — accuracy not yet measured
The References (page not provided) include a report of L. acidophilus bacteremia, supporting that species’ inclusion. The Abstract’s strain table names L. paracasei and L. plantarum as probiotics studied, not as causes of bacteremia. Our copy does not substantiate the claimed relative frequency or identify L. jensenii and L. fermentum as reported causes. (LLM, conf=0.82)
- Partly supportedcites [23] Salminen, 2006, Lactobacillus bacteremia, species identification, and antimicrobial susceptibility of 85 blood isolates, Clin. Infect. Dis. sourceExperimental — accuracy not yet measured
The Results and isolate-count tables (pages not supplied) document blood isolates of L. fermentum, L. jensenii, and L. plantarum, with fewer isolates than L. rhamnosus. Our copy does not document L. paracasei or L. acidophilus among the blood isolates; paracasei appears only in a reference about peritonitis, not bacteremia. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [26] Chazan, 2008, Bacteremia and pyelonephritis caused by Lactobacillus jensenii in a patient with urolithiasis, Isr. Med. Assoc. J.
- Not checked — no full text of the sourcecites [27] Matsuura, 2021, Lactobacillus bacteremia: A diagnostic clue of rectal cancer, QJM source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“One study reviewed cases reported over 5.5 years at a hospital in Boston, Massachusetts, and found of 21,652 patients admitted to their ICU who were not taking any probiotics, only two (0.009%) cases of LB were detected, which were caused by either L. acidophilus or Lpb. plantarum, but the specific strain was not reported [47].”
§ Lactobacillus Bacteremia and Probiotics: A Review > 3. Results > 3.6. Role of Probiotics in LB
What the sources say
- Partly supportedcites [47] Yelin, 2019, Genomic and epidemiological evidence of bacterial transmission from probiotic capsule to blood in ICU patients, Nat. Med. sourceExperimental — accuracy not yet measured
The paper reports two cases of Lactobacillus bacteremia (0.009%) among 21,652 ICU patients who did not receive an LGG-containing probiotic. It does not define that entire group as taking no probiotics: the Patient inclusion criteria and clinical data section says 645 ICU patients received probiotics, but only 522 received one containing LGG. The case count and rate match, but the claim broadens the comparison group incorrectly. (LLM, conf=0.91)
plainn = 21,652- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
44 more claims · 11 with their cited sources checked
Create a free account to see all 85 claims and to verify the 5 references still open.
- It may state two separate claims as one. 29
- Probably not a substantial claim. 10
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Lactobacillus Bacteremia and Probiotics: A Review > 3. Results > 3.7. Safety of Probiotics
“expectations that it will reach USD 72.9 billion by 2030”
§ Lactobacillus Bacteremia and Probiotics: A Review > References
“67. Allied Market Research. 2022. Probiotics Market Expected to Reach $73.9 Billion by 2030”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“Husni et al. reviewed cases of 45 patients over 15 years with clinically significant LB [6]. Twenty-two patients (44%) died during their hospitalization;”
§ Lactobacillus Bacteremia and Probiotics: A Review > 3. Results > 3.4. Consequences of LB
Reported 44 · recomputed 48.888889
Citations
Cites
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
Zheng, J., Wittouck, S., Salvetti, E., Franz, C. M. A. P., Harris, H. M. B., Mattarelli, P., O’Toole, P. W., Pot, B., Vandamme, P., Walter, J., et al. (2020) · International Journal of Systematic and Evolutionary Microbiology · doi:10.1099/ijsem.0.004107 · Cited by 3,313 · cited 1×
“Recently the identification of the genus Lactobacillus has been divided into 23 genera, >250 species, and 57 subspecies [17].”
BackgroundBeachey, E. H. (1981) · Journal of Infectious Diseases · doi:10.1093/infdis/143.3.325 · Cited by 1,411
Doron, S., & Snydman, D. R. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ085 · Cited by 942
Demonstration of safety of probiotics—A review
Salminen, S. (1998) · International Journal of Food Microbiology · doi:10.1016/s0168-1605(98)00128-7 · Cited by 884
van Prehn, J., Reigadas, E., Vogelzang, E. H., Bouza, E., Hristea, A., Guery, B., Krutova, M., Norén, T., Allerberger, F., Coia, J. E., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.09.038 · Cited by 640 · cited 1×
“Previous reviews and clinical practice guidelines have urged caution for probiotic use due to safety concerns [7,16,64].”
BackgroundMcFarland, L. V., Evans, C. T., & Goldstein, E. J. C. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00124 · Cited by 609
Self-citationLactobacillus Sepsis Associated With Probiotic Therapy
Land, M. H., Rouster-Stevens, K., Woods, C. R., Cannon, M. L., Cnota, J., & Shetty, A. K. (2005) · Pediatrics · doi:10.1542/peds.2004-2137 · Cited by 599 · cited 2×
“rhamnosus GG (ATCC53103) PCR 2 2 6 yr 6 wk AAD, CVC Yes No [57]”
BackgroundPathogenic relevance of Lactobacillus: A retrospective review of over 200 cases
Cannon, J. P., Lee, T. A., Bolanos, J. T., & Danziger, L. H. (2005) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-004-1253-y · Cited by 478 · cited 4×
“From a literature review of 241 cases of lactobacilli infections (129 cases of LB, 73 cases lactobacilli endocarditis, and 39 cases of localized lactobacilli infections), none were associated with probiotic exposure [25].”
BackgroundInfluentialSalminen, M. K., Rautelin, H., Tynkkynen, S., Poussa, T., Saxelin, M., Valtonen, V., & Jarvinen, A. (2004) · Clinical Infectious Diseases · doi:10.1086/380455 · Cited by 426 · cited 3×
“found that in patients with LB, the mortality was 26% at one month and 48% at one year [9].”
BackgroundInfluential
Research works printed but not linked: 1
- 2019, [Sepsis due to Lactobacillus reuteri in an extreme preterm newborn: Case report], Arch. Argent Pediatr., 117, e509
Cited by
Zhang, L., Xu, J.-Y., Xing, Y., Wu, P., Jin, Y.-W., Wei, W., Zhao, L., Yang, J., Chen, G., & Qin, L. (2024) · Microbiological Research · doi:10.1016/j.micres.2024.127821 · Cited by 56
Probiotics and their applications in functional foods: a health perspective
Amin, M. R., Biswas, A. P., Tasnim, M., Islam, M. N., & Azam, M. S. (2025) · Applied Food Research · doi:10.1016/j.afres.2025.101193 · Cited by 50
Engineered bacteria in tumor immunotherapy
Chen, H., Zhu, Y., Zhang, C., Hu, L. T., & Yang, K. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216817 · Cited by 42
Vaginal dysbiosis and the potential of vaginal microbiome-directed therapeutics
Valeriano, V. D., Lahtinen, E., Hwang, I., Zhang, Y., Du, J., & Schuppe‐Koistinen, I. (2024) · Frontiers in Microbiomes · doi:10.3389/frmbi.2024.1363089 · Cited by 51
“…organ transplantation), urogenital pathologies, congenital and valvular heart diseases or those who have undergone invasive procedures, that may be more susceptible to probiotic use (Salminen et al., 2004; Rossi et al., 2022; Salminen et al., 2006; Bapna et al., 2023; Kullar et al., 2023).”
Type 2 Diabetes and the Multifaceted Gut-X Axes
Guo, H., Pan, L.-T., Wu, Q., Wang, L., Huang, Z., Wang, J., Wang, L., Fang, X., Dong, S., Zhu, Y., et al. (2025) · Nutrients · doi:10.3390/nu17162708 · Cited by 42
Metadata
- Authors
- Kullar, R., Goldstein, E. J. C., Johnson, S., & McFarland, L. V.
- Affiliations
- Expert Stewardship Inc., Newport Beach, CA 92663, USA
- R.M. Alden Research Laboratory, Santa Monica, CA 90404, USA
- Edward Hines, Jr. VA Hospital (US)
- McFarland Consulting, Seattle, WA 98115, USA
- Corresponding author
- McFarland, Lynne V.
- Venue
- Microorganisms
- Publisher
- MDPI AG
- Published
- 2023-03-30
- Volume
- 11
- Issue
- 4
- Pages
- 896
- ISSN
- 2076-2607 (ISSN-L)
- PMC
- PMC10145752
- OpenAlex
- W4361274209
- Cited by
- 156
- References
- 80
- Citations by year
- 2026: 47 · 2025: 52 · 2024: 47 · 2023: 10
- FWCI
- 3.60
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Microorganisms (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Bio-K+
- Topics
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Keywords
- probiotics, probiotic safety, Lactobacillus rhamnosus GG, Lactobacillus plantarum, Lactobacillus paracasei, central venous catheters, immunosuppression, intensive care unit admission
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lactobacillus Bacteremia and Probiotics: A Review. https://app.cochat.ai/papers/10.3390/microorganisms11040896
- The paper
- Kullar, R., Goldstein, E. J. C., Johnson, S., & McFarland, L. V. (2023). Lactobacillus Bacteremia and Probiotics: A Review. Microorganisms. https://doi.org/10.3390/microorganisms11040896
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.